BSTG

Biostage, Inc. [BSTG] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BSTG Stock Summary

In the News

BSTG Financial details

Company Rating
-
Market Cap
57.82M
Income
-13.81M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
-4.12
Forward P/E
-
PEG
-0.76
P/S
-
P/B
16.46
P/C
-
P/FCF
-10.29
Quick Ratio
2.47
Current Ratio
2.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.14
EPS next Y
-
EPS next Q
-
EPS this Y
47.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-36.84%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-275%
ROE
-518%
ROC
-2.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-2%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.65-9.0
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
972
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.973019
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
BRK-B
3V64.DE
EMBASSY.NS
AMZ.DE
NVDA
Same Sector
RSLS
0HKD.L
EKTAY
MDWD
TVTY
Check Those
GUSH
000540.SZ
SCANFL.HE
1460.TW
001770.KS
Similar Market Cap
ANNX.ST
9810.HK
EBIZ
NMS
WPAY.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 972
  • Market Capitalization 57.82M
  • Employee 7
  • CEO Mr. Junli He
  • Headquarters Holliston,MA,US
  • IPO Date 2013-10-21
  • Website https://biostage.com

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.